Epocrates Appoints Board of Director Peter Brandt as Interim President and CEO

Epocrates, Inc. EPOC today announced Peter Brandt, a member of Epocrates' board of directors, has been appointed as the company's interim president and CEO. Brandt succeeds Rose Crane who stepped down from her position as president and CEO. The board has formed a search committee and initiated a search for a permanent replacement. "Under Rose's leadership, the company achieved an initial public offering, and she set the stage for future growth with the development and launch of innovative new products," said Patrick Jones, chairman of the Epocrates board of directors. "We thank Rose for her commitment and contributions and wish her well in her future endeavors." Peter Brandt, who joined the company's board of directors in February 2011, has more than thirty years experience in the pharmaceutical industry. He most recently held the position of president and CEO of Noven Pharmaceuticals. He currently serves on the board of directors for Rexahn Pharmaceuticals, Auxilium Pharmaceuticals and the Population Council. "Peter's strong leadership and extensive knowledge of the healthcare industry will benefit the company during this transition," said Jones. "We are fortunate that Peter is ready to step in and maintain positive momentum driving the company forward."